{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:45:03Z","timestamp":1792100703471,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"DOI":"10.1007\/s13555-026-01958-w","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:03:04Z","timestamp":1792098184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis\u2014A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"di Vico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bighetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul Armando","family":"Luyo Saboya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia Veronica","family":"Di Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Manzo Margiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Cristallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Francesca","family":"Cavaliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Magliulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Podo Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero Cascio","family":"Ingurgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Carpentieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Campoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Assorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Rongioletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Graziella","family":"Burroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eustachio","family":"Nettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pezzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Bruno","family":"Guanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"12","key":"1958_CR1","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Z\u00e4ch S, Taieb A, et al. ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717\u201344. https:\/\/doi.org\/10.1111\/jdv.16892.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1958_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137. https:\/\/doi.org\/10.1016\/j.anai.2018.07.006.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"1958_CR3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331. https:\/\/doi.org\/10.1111\/jdv.18345.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10290","key":"1958_CR4","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up\u00a01 and Measure Up\u00a02): results from two replicate double-blind, randomised controlled phase\u00a03 trials. Lancet. 2021;397(10290):2151\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2.","journal-title":"Lancet"},{"issue":"9","key":"1958_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1958_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40257-023-00788-2","volume":"24","author":"K Reich","year":"2023","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: results from the 52-week randomized, placebo-controlled phase\u00a03 AD Up study. Am J Clin Dermatol. 2023;24(4):669\u201381. https:\/\/doi.org\/10.1007\/s40257-023-00788-2.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1958_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40257-023-00798-0","volume":"24","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Ortoncelli M, Schena D, et al. Long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: an interim analysis through 48\u00a0weeks of observation. Am J Clin Dermatol. 2023;24(6):953\u201361. https:\/\/doi.org\/10.1007\/s40257-023-00798-0.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1958_CR8","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1111\/jdv.19507","volume":"38","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Piscazzi F, et al. Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: a 52-week retrospective study. J Eur Acad Dermatol Venereol. 2024;38(2):e152\u20134. https:\/\/doi.org\/10.1111\/jdv.19507.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1958_CR9","doi-asserted-by":"publisher","first-page":"adv00402","DOI":"10.2340\/00015555-3751","volume":"101","author":"M De Bruin-Weller","year":"2021","unstructured":"De Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402. https:\/\/doi.org\/10.2340\/00015555-3751.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1958_CR10","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139\u201348. https:\/\/doi.org\/10.1111\/jdv.20229.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1958_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamadermatol.2026.0662","volume":"162","author":"JF Merola","year":"2026","unstructured":"Merola JF, Childs BA, Bartley BR, et al. International Eczema Council definitions of low disease activity and remission in atopic dermatitis: a consensus statement. JAMA Dermatol. 2026;162(6):631\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2026.0662.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1958_CR12","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s13555-024-01242-9","volume":"14","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt A, Eyerich K, Irvine AD, et al. More time spent with clear skin and no itch with upadacitinib versus dupilumab for atopic dermatitis. Dermatol Ther (Heidelb). 2024;14(9):2621\u201330. https:\/\/doi.org\/10.1007\/s13555-024-01242-9.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1958_CR13","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0553","author":"AI Rodriguez-Sanna","year":"2025","unstructured":"Rodriguez-Sanna AI, Montero-Vilchez C, Moreno-Suarez FG, et al. Patients with atopic dermatitis treated with upadacitinib: factors related to achieving minimal disease activity. Dermatitis. 2025. https:\/\/doi.org\/10.1089\/derm.2024.0553.","journal-title":"Dermatitis"},{"key":"1958_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70558","author":"IA Koumprentziotis","year":"2026","unstructured":"Koumprentziotis IA, Tsiogka A, Kleidona IA, Vaiopoulos A, Stratigos A, Gregoriou S. Sustained minimal disease activity with upadacitinib and abrocitinib in moderate-to-severe atopic dermatitis: a 104-week, real-world, retrospective study. Int J Dermatol. 2026. https:\/\/doi.org\/10.1111\/ijd.70558.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1958_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up\u00a01 and Measure Up\u00a02 randomized clinical trials. JAMA Dermatol. 2022;158(4):404\u201313. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0029.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1958_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40257-024-00853-4","volume":"25","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham MJ, Paller AS, et al. Early and sustained improvements in symptoms and quality of life with upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: 52-week results from two phase\u00a0III randomized clinical trials (Measure Up\u00a01 and Measure Up\u00a02). Am J Clin Dermatol. 2024;25(3):485\u201396. https:\/\/doi.org\/10.1007\/s40257-024-00853-4.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1958_CR17","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1007\/s13555-025-01485-0","volume":"15","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate-to-severe atopic dermatitis: integrated analysis of phase\u00a03 studies (Measure Up\u00a01 and 2). Dermatol Ther (Heidelb). 2025;15(9):2583\u201394. https:\/\/doi.org\/10.1007\/s13555-025-01485-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"1958_CR18","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/ddg.15908","volume":"23","author":"F Manzo Margiotta","year":"2025","unstructured":"Manzo Margiotta F, Dini V, Calabrese L, et al. Upadacitinib dose adjustment in moderate-to-severe atopic dermatitis: insights from a multicenter real-world study. JDDG. 2025;23(12):1597\u2013600. https:\/\/doi.org\/10.1111\/ddg.15908.","journal-title":"JDDG"},{"issue":"1","key":"1958_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","volume":"151","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase\u00a03 studies. J Allergy Clin Immunol. 2023;151(1):172\u201381. https:\/\/doi.org\/10.1016\/j.jaci.2022.09.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1958_CR20","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","volume":"87","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase\u00a03 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87(4):784\u201391. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.012.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01958-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01958-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01958-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:03:05Z","timestamp":1792098185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01958-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":20,"alternative-id":["1958"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01958-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"13 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luca Potestio has been a consultant and\/or speaker for AbbVie, Almirall, Johnson and Johnson, and UCB Pharma. Matteo Bianco has been a speaker for BMS. Luca Mastorino served as speaker and advisory board member for LEO Pharma, Almirall, Novartis, Eli Lilly, Accord, Pierre Fabre, UCB, and Johnson & Johnson. Francesca Maria Gaiani acted as a speaker or consultant for Novartis, AbbVie, Eli Lilly, Celgene, LEO Pharma, and Almirall. Stefano Bighetti received honoraria for lectures from Pfizer. Martina Maurelli has been a paid speaker for Almirall, Johnson & Johnson Innovative Medicine, and LEO Pharma. Flavia Manzo Margiotta declares conflicts of interest with Eli Lilly, AbbVie, Almirall, Sanofi, LEO Pharma, and Pfizer. Andrea Carugno has been a speaker and\/or consultant for Almirall, Amgen, AbbVie, Boehringer Ingelheim, Eli Lilly, LEO Pharma, Janssen-Cilag, Novartis, and UCB Pharma. Ruggero Cascio Ingurgio has served as a consultant for UCB Pharma. Giulia Carpentieri declares no conflicts of interest. Franco Rongioletti declares conflicts of interest with AbbVie, Almirall, Sanofi, Lilly, and UCB. Nicola Zerbinati was a scientific director of Matex Lab. Maria Concetta Fargnoli has served on advisory boards and received honoraria for lectures and\/or research grants from Amgen, Almirall, AbbVie, Boehringer Ingelheim, BMS, Galderma, Kyowa Kirin, Incyte, LEO Pharma, Pierre Fabre, UCB, Eli Lilly, Pfizer, Johnson & Johnson, MSD, Novartis, Sanofi, Regeneron, and Sun Pharma. Maria Esposito has served as speaker\/consultant for AbbVie, Amgen, Almirall, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, UCB, and Sanofi-Regeneron. Marco Romanelli declares conflicts of interest with Eli Lilly, AbbVie, Novartis, Janssen, Almirall, Sanofi, LEO Pharma, UCB, and Urgo. Anna Balato has served as speaker and\/or has received fees from AbbVie, Almirall, Amgen, BI, BMS, Eli Lilly, Janssen, Incyte, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB. Giampiero Girolomoni has received personal fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, LEO Pharma, Merck Serono, Novartis, Pfizer, Samsung Bioepis, and Sanofi. Elena Pezzolo has received personal fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Eli Lilly, Incyte, Johnson & Johnson, LEO Pharma, Novartis, Pfizer, and Sanofi outside the submitted work. Mario Bruno Guanti declares conflicts of interest with AbbVie, Pfizer, Sanofi, Lilly, Unifarco, LEO Pharma, Almirall, and Firma. Mariateresa Rossi has served on advisory boards and received honoraria for lectures from Almirall, AbbVie, LEO Pharma, Sanofi Genzyme, Galderma, L\u2019Or\u00e9al, and Pfizer. Cataldo Patruno has acted as speaker, consultant and\/or advisory board member for AbbVie, Almirall, Amgen, Galderma, LEO Pharma, Lilly, Novartis, Pfizer, Pierre Fabre, and Sanofi. Maddalena Napolitano has acted as speaker, consultant and\/or advisory board member for AbbVie, Eli Lilly, LEO Pharma, Novartis, Incyte, and Sanofi. Angelo Valerio Marzano has received disease-relevant honoraria for consultancy and advisory board activities from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Incyte, and Johnson & Johnson, LEO Pharma, MSD, Novartis, Otsuka, Pfizer, Sanofi, Takeda, and UCB. Silvia Mariel Ferrucci served as principal investigator in clinical trials, speaker or advisory board member for AbbVie, Almirall, Amgen, Bayer, Eli Lilly, Sanofi, Pfizer, LEO Pharma, and Novartis. Piergiorgio Malagoli has been a speaker for AbbVie, Lilly, Novartis, Janssen-Cilag, Celgene, LEO Pharma, and Almirall. Michela Ortoncelli has been an advisor, consultant, speaker and\/or investigator for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and UCB. Simone Ribero received research grants, travel support and consultancy fees from AbbVie, Almirall, LEO Pharma, J&J, L\u2019Or\u00e9al, Sanofi, Sandoz, UCB, Eli Lilly, Novartis, BMS, and Incyte. Antonio Costanzo has served as an advisory board member and consultant and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. Alessandra Narcisi has served on advisory boards and received honoraria for lectures and research grants from Almirall, AbbVie, LEO Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen, and Boehringer Ingelheim. Diego Orsini has been a speaker and\/or consultant for AbbVie, LEO Pharma, UCB, Bristol Meyers Squibb, and Boehringer Ingelheim. Mariateresa Rossi, Maddalena Napolitano and Diego Orsini are Editorial Board members of\n                      Dermatology and Therapy\n                      . Mariateresa Rossi, Maddalena Napolitano and Diego Orsini were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Francesca Barei declares no conflicts of interest. Francesca di Vico declares no conflicts of interest. Raul Armando Luyo Saboya declares no conflicts of interest. Eugenia Veronica Di Brizzi declares no conflicts of interest. Mattia Cristallo declares no conflicts of interest. Anna Francesca Cavaliere declares no conflicts of interest. Manfredi Magliulo declares no conflicts of interest. Antonio Podo Brunetti declares no conflicts of interest. Francesco Messina declares no conflicts of interest. Marco Campoli declares no conflicts of interest. Chiara Assorgi declares no conflicts of interest. Massimo Gola declares no conflicts of interest. Francesco Loconsole declares no conflicts of interest. Anna Graziella Burroni declares no conflicts of interest. Eustachio Nettis declares no conflicts of interest. Pietro Morrone declares no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the present analysis was obtained within the framework of the ongoing LANDSCAPE clinical registry. The specific amendment covering the present analysis was approved by the Territorial Ethics Committee of the Calabria Region (Comitato Etico Territoriale Regione Calabria; Protocol No. 164\/2026) on June 22, 2026. The study was conducted in accordance with the principles of the Declaration of Helsinki, and all participants had provided written informed consent for the use of their anonymized clinical data within the registry.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}